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Abstract
Background: Cancers often arise within an area of cells (e.g. an epithelial patch) that is predisposed to the
development of cancer, i.e. a “field of cancerization” or “field defect.” Sporadic colon cancer is characterized by an
elevated mutation rate and genomic instability. If a field defect were deficient in DNA repair, DNA damages would
tend to escape repair and give rise to carcinogenic mutations.
Purpose: To determine whether reduced expression of DNA repair proteins Pms2, Ercc1 and Xpf (pairing partner
of Ercc1) are early steps in progression to colon cancer.
Results: Tissue biopsies were taken during colonoscopies of 77 patients at 4 different risk levels for colon cancer,
including 19 patients who had never had colonic neoplasia (who served as controls). In addition, 158 tissue
samples were taken from tissues near or within colon cancers removed by resection and 16 tissue samples were
taken near tubulovillous adenomas (TVAs) removed by resection. 568 triplicate tissue sections (a total of 1,704
tissue sections) from these tissue samples were evaluated by immunohistochemistry for 4 DNA repair proteins.
Substantially reduced protein expression of Pms2, Ercc1 and Xpf occurred in field defects of up to 10 cm
longitudinally distant from colon cancers or TVAs and within colon cancers. Expression of another DNA repair
protein, Ku86, was infrequently reduced in these areas. When Pms2, Ercc1 or Xpf were reduced in protein
expression, then either one or both of the other two proteins most often had reduced protein expression as well.
The mean inner colon circumferences, from 32 resections, of the ascending, transverse and descending/sigmoid
areas were measured as 6.6 cm, 5.8 cm and 6.3 cm, respectively. When combined with other measurements in the
literature, this indicates the approximate mean number of colonic crypts in humans is 10 million.
Conclusions: The substantial deficiencies in protein expression of DNA repair proteins Pms2, Ercc1 and Xpf in about 1
million crypts near cancers and TVAs suggests that the tumors arose in field defects that were deficient in DNA repair
and that deficiencies in Pms2, Ercc1 and Xpf are early steps, often occurring together, in progression to colon cancer.
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Background
Field defects
The term “field cancerization” was first used in 1953 to
describe an area or “field” of epithelium that has been
preconditioned by (at that time) largely unknown pro-
cesses so as to predispose it towards development of
cancer [1]. Since then, the terms “field cancerization”
and “field defect” have been used to describe pre-malig-
nant tissue in which new cancers are more likely to
arise, and the concept of field cancerization in clinical
oncology has received increasing attention [2,3]. For
example, colon cancer patients are at about 9% to 55%
risk for development of a second colon cancer in the
next 5 years after a first cancer is resected [4], while
members of the general population have less than a 1%
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period.
Field defects in the colonic mucosa
Field defects in the colonic mucosa probably arise by
natural selection of a mutant or epigenetically altered
cell among the stem cells of a crypt. The stem cells of a
human crypt consist of about 10-20 cells at the base of
a crypt in an area designated a stem cell niche [5,6].
With natural selection, a mutant or epigenetically
altered stem cell may replace the other stem cells in a
crypt, in a process called niche succession [7]. Genetic
instability or a mutator phenotype, due to loss of DNA
repair or loss of apoptosis competence, would accelerate
this process [8]. If, among the stem cells in a colonic
crypt, a cell acquires an advantage through a mutation
or an epimutation, it will tend to expand clonally at the
expense of neighboring stem cells. This process may
give rise to “crypt conversion,” whereby cells with a
mutant or epigenetically altered genotype replace the
other cells in the stem cell “niche” and generate an
altered genotype for the entire cell population of a colo-
nic crypt [9,10]. A human colonic crypt is shaped like a
test-tube and consists of about 2,500 to 5,000 cells [11],
being about 85 to 106 cells in length and about 29-43
cells in circumference [12].
After one crypt is converted to a mutated or epigen-
eticaly altered crypt, a field defect may be formed by
successive crypt fissions [10]. Thus, a patch of abnormal
tissue may arise (a patch of many neighboring crypts in
the epithelium of the colon, represented by the outer-
most irregular rings in Figure 1). Within a patch, a sec-
ond such mutation or epigenetic alteration may occur
so that a given crypt acquires an advantage compared to
other crypts within the patch, and this crypt may
expand clonally forming a secondary patch within the
original patch. Within this new patch, the process may
be repeated multiple times until a malignant stem cell
arises which clonally expands into a cancer (dark area in
Figure 1). If this is the general process by which spora-
dic colonic adenocarcinomas arise, then colonic adeno-
carcinomas generally should be associated with, and be
preceded by, fields of increasing abnormality reflecting
the succession of premalignant events. The most exten-
sive regions of abnormality (the outermost irregular
rings in Figure 1) would reflect the earliest events in
carcinogenesis.
Genomic instability in cancer
Colon cancer is a disease associated with genomic
instability [13]. Colon cancers have between 49 to 111
non-silent mutations, with an average of 15 of those
mutations being “drivers” of carcinogenesis, and the
remaining ones being “passengers” [14]. However, there
is no clear common pattern of mutations in different
colon cancers. In addition, there is a median of 9 copy
number changes (homozygous deletions and amplifica-
tions of genes) per colon cancer [15]. But it has been a
puzzle as to how this instability originates. However, we
note that if an early event in the development of a field
defect were loss of DNA repair capability, this would
allow DNA damages to escape repair and could give rise
to the increased mutations and chromosome aberrations
that are characteristic of cancer.
Reactive oxygen species and their specific targets
As reviewed by Ziech et al. [16], reactive oxygen species
(ROS) play an important role in progression to cancer.
ROS cause reduction in expression of at least two key
DNA repair enzymes, Ercc1 and Pms2, in vitro.C h a n g
e ta l .[ 1 7 ]s h o w e dt h a te l e v a t e dR O Sd e g r a d eP m s 2b u t
not two other mismatch repair proteins (Mlh1 and
Msh2) suggesting that Pms2 is a specific target of oxida-
tive stress.
Exposure of human cells to a non-toxic level of H2O2
caused a 5-fold decrease in expression of Ercc1, possibly
by direct oxidative attack of the protein [18]. In contrast,
expression of several other nucleotide excision repair pro-
teins (e.g. Xpa, Xpc, Ercc4 and Ercc5) increased 2 to 4.5-
fold, suggesting that Ercc1 is also a specific target of oxida-
tive stress. Nucleotide excision repair capacity decreased
to less than 50% by the H2O2 treatment in a manner that
correlated with loss of Ercc1 [18].
Roles of Pms2 and Ercc1
Due to the important role of ROS in cancer and the
indication that Pms2 and Ercc1 are specific targets of
5
Figure 1 Schematic diagram of colonic mucosa indicating
progression of a field defect to colon cancer. The gray area
within the right-hand set of irregular concentric areas indicates a
colon cancer. The outermost irregular concentric areas indicate
initial defects with a selective advantage. A next smaller concentric
area indicates a secondary mutation or epimutation giving a further
selective advantage, while still smaller areas indicated further
mutations or epimutations with still further selective advantages.
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Pms2 and Ercc1 (and Xpf, the pairing partner of Ercc1)
were systematically reduced in progression to colon can-
cer. In a previous preliminary study we found that tissue
samples from patients with large tubulovillous adenomas
or adenocarcinomas had reduced Pms2 expression in
cell nuclei at the bases of crypts (including the stem cell
regions) near these tumors. This reduction was asso-
ciated with reduced apoptosis competence [19], as
might be expected since Pms2 is also needed for apop-
tosis [20]. Ku86 was added to our study due to Rigas et
al. [21] indicating that a r e d u c t i o ni nK u 8 6c o u l db e
important during human colon carcinogenesis.
Germline mutations in DNA mismatch repair genes
give rise to hereditary non-polyposis colon cancer,
which accounts for about 2.2% of colon cancer [22]. In
the human DNA mismatch repair system, Pms2 inter-
acts with Mlh1 to form the MutLa heterodimer, and
Pms2 is unstable in the absence of Mlh1 [23]. The
Mlh1/Pms2 protein complex, together with other com-
ponents of the mismatch repair system, corrects single
base mismatches and small insertion/deletion loops that
occur during DNA replication.
In mice, the Pms2/Mlh1 heterodimer is also required
for the normal apoptotic response to DNA damage [24].
Pms2 is a dual role protein, needed for DNA repair and
also for apoptosis (reviewed in [20]). Pms2 mediates the
apoptotic response through interaction with p73, a p53-
related protein, and p73, like p53, is an activator of
apoptosis [25]. Decreased apoptosis capability in Pms2
deficient mice allows cells with DNA alkylation damages
to survive, leading to increased mutation [24]. Mice with
deficient Pms2 have a 100-fold elevated level of sponta-
neous mutation [26].
The human Ercc1/Xpf complex is a DNA endonu-
clease essential for one of the two incision steps of
nucleotide excision repair (NER), a DNA repair pathway
that removes helix-distorting DNA damages. Ercc1/Xpf
endonuclease incises the DNA on the 5’ side of the
damaged site. The NER repair system can repair oxida-
tive DNA damages such as 8-oxoguanine [27]. The
Ercc1/Xpf complex also facilitates repair of DNA dou-
ble-strand breaks [28] and inter-strand crosslinks [29],
presumably through the process of homologous recom-
binational repair [30]. Mice deficient for Ercc1 show
accelerated mutation accumulation [31]. Mice with skin-
specific Ercc1 inactivation are hypersensitive to UV-
induced skin cancer [32].
Results
Expression of Pms2, Ercc1 and Xpf in tissue samples from
individuals who never had a colonic neoplasm
The levels of expression of DNA repair proteins Pms2,
Ercc1 and Xpf were evaluated by immunohistochemistry
(IHC) in sequential tissue sections from individuals who
never had a colonic neoplasm, and thus are at low risk
of colon cancer. The 4 micron tissue sections were
placed on sequential slides and separately immunos-
tained for Pms2, Ercc1 and Xpf. Crypts are usually
about 60 to 80 microns in width, when measured
through crypts for which the crypt lumen is visible, so
that the cut through the crypt is through the central
region of the crypt. Since the tissue sections were 4
microns thick, a series of about 15 sequential tissue sec-
tions could be cut through the same crypt and be dis-
played on separately immunostained slides.
F i g u r e2s h o w st h es a m ec r y p ti m m u n o s t a i n e dw i t h
antibodies to Pms2, Ercc1 and Xpf. The cells of this
crypt had high expression of Pms2, Ercc1 and Xpf in
the nuclei of most of the cells of the crypts.
While Pms2 is expressed at high level in nuclei of
absorptive cells throughout the major portion of the
crypt, at the open top of the crypt, near the colonic
lumen, there is reduced nuclear expression of Pms2
(Figure 2, panel A). This pattern of expression of Pms2
is typical for crypts within the colonic epithelium of
patients at low risk for colon cancer.
A similar pattern of nuclear expression is seen for Xpf
in the epithelium of patients at low risk for colon can-
cer, except that Xpf is sometimes expressed at high
levels, and sometimes at low levels, in areas of the colo-
nic epithelium between crypts. The pattern for Ercc1 in
low risk patients, however, is to have high nuclear
expression in all absorptive cells, both within the crypts
and along the epithelium of the colonic lumen.
Expression of Pms2, Ercc1 and Xpf in histologically
normal tissue samples taken from colonic resections that
include an adenocarcinoma
For convenience in further discussion, we refer to three
regions of the colonic crypt and adjacent mucosa as illu-
strated in Figure 3. These regions are the main body of
the crypt, a region near the colonic lumen referred to as
the “neck”, and the surface epithelium of the colonic
lumen that is present between crypts. The three crypts
shown in Figure 3 were each located about 10 cm from
a colonic adenocarcinoma. We evaluated nuclear stain-
ing of absorptive cells of a crypt as being at levels 0, 1,
2, 3, or 4, with 0 indicating no detectable staining, 1
indicating just barely detectable staining, 2 indicating
low but clearly present staining, 3 indicating moderately
strong staining, and 4 indicating a very high level of
staining. Scoring was performed with observations both
in a Motic digital BA300 photomicroscope at 400×, and
as digital images at 400× on a high contrast ratio com-
puter monitor.
Figure 3 shows images taken at 200× (to allow entire
crypts to be seen in a single view), but even at this
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ing for Pms2 within the crypt is at level 0. In Figure 3
panel B, staining for Ercc1 was largely at levels 0, 1 or 2
in the body of the crypt, while in the neck and the sur-
face regions nuclear staining was at levels 3 or 4.
In Figure 3 panel C, staining for Xpf was at level 0 or
1 in the body of the crypt, level 2 at the neck of the
crypt and level 0 or 1 at the surface.
When evaluating staining of absorptive cells in the
bodies of individual crypts, or in crypt bodies overall in
a tissue section, we designate levels 3 and 4 as high
expression and levels 0, 1 and 2 as reduced expression.
A frequent finding was that tissue samples defective in
one of the proteins Pms2, Ercc1 or Xpf were simulta-
neously defective in one or both of the other proteins.
Figure 4 shows sequential sections of histologically nor-
mal tissue taken 10 cm away from an adenocarcinoma
stained either for Pms2 (A), Ercc1 (B) or Xpf (C). In
each case the crypts have reduced staining for the
respective proteins in all cells in the bodies of the
crypts. This contrasts with the strong pattern of staining
observed in sequential sections from low risk individuals
(Figure 2).
Figure 5 shows sequential cross sections through a
group of colonic crypts stained for Pms2 (A), Ercc1 (B),
or Xpf (C). The fissioning crypts (indicated by arrows) in
these panels are each deficient in Pms2, Ercc1 and Xpf.
These crypts illustrate a possible newly deficient stage in
the formation of a field defect, expanding by crypt fission.
The DNA repair protein deficiencies they show have
likely relevance to progression to colon cancer.
Figure 6 shows sequential sections through another
group of colonic crypts stained for Pms2, Ercc1 or Xpf.
The sections were from histologically normal tissue 10
cm from a colonic adenocarcinoma. The figure shows a
crypt apparently fissioning into three crypts. There is
high expression of Ercc1, but reduced expression of
Pms2 and Xpf. This figure illustrates a common obser-
vation, that two of the three measured proteins may be
simultaneously deficient, but not necessarily all three.
Absorptive cells and goblet cells are the two predomi-
nant types of cells in the colonic crypt epithelium.
When evaluating cells of the body of a crypt for level of
expression of Pms2, Ercc1 or Xpf, only absorptive cells
were evaluated since their expression was consistently
high in low risk patients. The goblet cells, each with a
large “balloon like” region containing mucin granules
(white areas under these staining conditions), often had
low or absent expression for the protein of interest,
even in relatively lower risk patients, as shown in Figure
7. The several thousand goblet cells of a crypt arose
from the few stem cells at the base of the crypt, as did
the absorptive cells of the crypt. The frequent lack of
expression for Pms2, Ercc1 or Xpf in goblet cells
appears to indicate a possible epigenetic alteration dur-
ing their differentiation.
Figure 2 Sequential sections of the same crypt with high expression of Pms2 (A), Ercc1 (B) and Xpf (C). This crypt, from the biopsy of a
58 year old male patient who never had colonic neoplasia, shows high expression (brown) in absorptive cell nuclei throughout most of the
crypt for each of the proteins. Note that Pms2 and Xpf expression (in panels A and C) are each reduced or absent in the nuclei of cells at the
top of the crypt and within the surface of the colonic lumen between crypts. Images taken at 200×.
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carcinoma are deficient in expression of Pms2, Ercc1 or
Xpf, they are also often similarly deficient in all of the
crypts within the tissue section. A deficient crypt near a
colon cancer is most often part of a large patch of defi-
cient cells. To illustrate this, Figure 8A shows an entire
tissue section, with about 40 crypts in the section, with
normal high staining for Pms2 and Figure 8B shows an
entire tissue section with about 100 crypts, all deficient
for Pms2. Similarly Figure 8C shows an entire tissue
section (sequential to that shown in panel A) with high
staining for Xpf, and Figure 8D shows an entire tissue
section, all with reduced staining for Xpf within the
bodies of the crypts, although there is high staining
along the surface of the colonic lumen.
Expression of Ku86 in histologically normal tissue
samples taken from colonic resections that include an
adenocarcinoma
As described above, the pattern of deficiency shown by
Pms2, Ercc1 and Xpf is that, most often, when one or
more of these proteins are reduced in expression, all the
crypts of the tissue section are similarly deficient. That
is, the patch size of the field defect is large. Ku86 defi-
cient crypts, however, tend to occur in small patches of
1 to 3 crypts with reduced staining. Figure 9 shows a
section of colonic mucosa that has a patch of 3 crypts
with reduced expression of Ku86 and with all nearby
crypts expressing high levels of Ku86.
Semi-quantitative evaluation of Pms2, Ercc1, Xpf and
Ku86 in histologically normal tissues and in colon cancers
To make a semi-quantitative estimate of the degree of
deficiency of Pms2, Ercc1, Xpf and Ku86 in areas sur-
rounding colon cancers, the level of expression of these
proteins in histologically normal tissue of patients who
never had a colonic neoplasia was first evaluated. Such
individuals have about a 2.4% chance of developing an
advanced colonic neoplasia within the next 5.5 years
[33], and thus presumably have few genetic or epigenetic
alterations leading to progression to colon cancer.
The absorptive cells in the “bodies” of crypts of an
entire tissue section were evaluated for percent of cells
Figure 3 Single crypts having deficient expression for Pms2
(A), Ercc1 (B) or Xpf (C). These crypts are from a histologically
normal area of a colon resection of a male patient who had an
adenocarcinoma in the sigmoid colon. When Pms2 is deficient,
typically all the cells of the crypt have low or absent expression for
Pms2 (A). When Ercc1 is deficient, cells of the “body” have reduced
or absent expression of Ercc1 but cells of the “neck” and “surface”
usually have high expression for Ercc1 (B). When Xpf is deficient,
cells of the body have reduced or absent expression of Xpf, but
cells of the neck region often have high expression of XPF. Cells at
the surface may have reduced expression (C) or may have high
expression for Xpf (not shown here but see Figure 4). Images taken
at 200×.
Figure 4 Sequential tissue sections with all crypts having reduced “body” expression of Pms2 (A), Ercc1 (B) and Xpf (C). These crypts
are from a histologically normal area of a colon resection of a male patient who had an adenocarcinoma in the sigmoid colon (same tissue as
in Figure 3). There is high expression of Ercc1 at the neck and surface of the crypts (B). There is also some expression of Xpf at the neck of each
crypt but not in the clonic lumen in this area of tissue (C). For Pms2 (A), there is reduced expression in the body, the neck and surface for all
epithelial cells. Images taken at 200×.
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proteins Pms2, Ercc1, Xpf and Ku86. Pms2, Ercc1 and
Xpf were evaluated in triplicate sequential 4 micron tis-
sues sections of the same tissue samples. Ku86 tissue
samples were from similar, but not identical, tissues to
those evaluated for Pms2, Ercc1 and Xpf.
Tissue sections were prepared from 19 patients who
never had any colonic neoplasia and were immunos-
tained with antibodies to Pms2, Ercc1 and Xpf. Tissue
sections from 10 such patients were immunostained
with antibodies to Ku86. These minimal risk individuals
were labeled category “A” and box and whisker plots
were made of the percent of absorptive cells with high
expression of the four proteins Pms2, Ercc1, Xpf or
Ku86 in the colonic crypts.
Although the standard deviation is ordinarily used to
decipher the spread of data when values follow a sym-
metrical distribution, box and whisker plots are pre-
ferred when data are asymmetrically distributed and
contain outliers. In this type of plot, the median value is
marked by a horizontal line within the box. The ends of
the box mark the upper and lower quartiles, so the box,
itself, spans the range of the two internal quartiles. The
whiskers are the two lines outside the box that extend
to the highest and lowest observations (except for the
outliers). Outliers are indicated as individual points.
As can be seen in Figure 10, for patients labeled A,
who are at minimal risk for progression towards colon
cancer, the median percents of absorptive cells with
high expressions of Pms2, Ercc1, Xpf and Ku86 in their
tissue sections were each above 90%, and at least 75% of
all tissue sections of these lowest risk patients had more
than 90% of the absorptive cells with high expression of
all 4 proteins (values within the box plus within whis-
kers with higher values).
We were also interested in whether deficiencies in
protein expression of Pms2, Ercc1, Xpf or Ku86 could
be biomarkers of colon cancer risk within biopsies taken
during colonoscopies. We stratified patients whose biop-
sies were obtained and who did have some level of colo-
nic neoplasia into categories B, C, and D. Patients who
had a current or previous record for a total of 1 to 3
adenomas that were less than 1 cm in diameter were
labeled B. Patients with a current or previous record of
an advanced neoplasia (with either adenoma > 1 cm, vil-
lous adenoma, or adenoma with dysplasia) were labeled
C. Patients with a current or previous record of colon
cancer were labeled D. These groups were comparable
to the groups stratified by Lieberman et al. [33]. In the
5.5-year follow-up of more than 1,000 patients, Lieber-
man et al. [33] found that patients similar to our group
B had a 6.1% chance, those similar to our group C had
about a 16% chance, and patients similar to our group
D had a 34.8% chance of developing an advanced colo-
nic neoplasia within the next 5.5 years.
Figure 10 indicates that the median percent of absorp-
tive cells with high expression of Pms2, Ercc1, Xpf and
Ku86 in their tissue sections were each above 90% for
the patients in groups B, C and D. Thus, these proteins
would not make good biomarkers for risk of colon
cancer.
There were also 32 tissue samples obtained at 1-10 cm
from colon cancers (removed during resection) that
were cut as triplicates and immunostained for Pms2,
Ercc1 and Xpf, as well as 38 additional tissue samples
obtained at 1-10 cm from colon cancers that were
immunostained for Ku86. These were labeled E in Fig-
ure 10. In addition, 27 tissue samples obtained as sam-
ples of colon cancers had marginal tissue attached with
histologically normal colonic morphology that were
Figure 5 Tissue with fissioning crypts stained for Pms2 (A), Ercc1 (B) and Xpf (C). These sequential sections were from histologically
normal tissue marginal to a resected sigmoid adenocarcinoma of a female patient. There appear to be fissioning crypts in this area of tissue,
indicated by arrows. These fissioning crypts have reduced expression for each of the three proteins, Pms2, Ercc1 and Xpf. Most of the other
crypts in this area have high expression of Pms2, Ercc1 and Xpf in their cell nuclei. These fissioning crypts may constitute a small patch of DNA
repair-defective crypts that are increasing in patch size by crypt fission. Images taken at 200×.
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triplicate and immunostained for Pms2, Ercc1 and Xpf,
and 3 such tissue samples were cut and immunostained
for Ku86. These marginal tissue samples were labeled F
in Figure 10. A total of 47 samples of colon cancers (the
27 with marginal tissues included and 20 without mar-
ginal tissues) were cut in triplicate and immunostained
for Pms2, Ercc1 and Xpf, plus a total of 11 colon can-
cers (3 with marginal tissues and 8 without marginal tis-
sues) were sectioned and immunostained for Ku86.
Tissues from within cancers were labeled G in Figure
10.
For the three tissue groups labeled E, F and G, the
levels of expression of Pms2, Ercc1 and Xpf are much
more broadly distributed and the median values are
lower than in groups A-D. In contrast, for Ku86, the tis-
sue groups labeled E and F do not show a lower median
v a l u et h a ns h o w ni ng r o u p sA - D ,a n do n l yg r o u pG ,
within the cancers shows a lower median value. For
Ku86, the range in values is not as great as the range in
values for Pms2, Ercc1 and Xpf in groups E, F and G.
That is, there is less variabi l i t ya n dm u c hl e s sl o s so f
expression for Ku86 than for Pms2, Ercc1 and Xpf in
comparable tissues.
In general, these results show that expression of Ercc1,
Xpf and Pms2 is reduced and more variable (among tis-
sue samples) in the colonic mucosa nearby or within
tumors, compared to the colonic mucosa from biopsies
taken during colonoscopies.K u 8 6i sl e s sf r e q u e n t l y
reduced in expression in tissues near tumors, and has a
more modest reduction within tumors than the other
three DNA repair proteins evaluated.
Expression of Pms2, Ercc1 and Xpf in pairwise
associations
In Figures 4, 5 and 6 we illustrated the frequent finding
that tissues are often simultaneously deficient for two or
all three of the proteins Pms2, Ercc1 or Xpf. We next
measured the frequencies with which pairwise combina-
tions of these proteins (Pms2 & Ercc1; Pms2 & Xpf;
Ercc1 & Xpf) are deficient in expression of both pro-
teins together in the same tissue.
As noted above, the expression values for Pms2, Ercc1
and Xpf are asymmetrically distributed in tissues near
or within tumors. On the other hand, the expression
values of Pms2, Ercc1 and Xpf for the lowest risk group,
group A, have an approximately symmetric distribution,
and so the mean and standard deviation s can be calcu-
lated. The mean expression level ± 2s can be taken as
the range in which 95% of the expression values are
expected to fall. If the lowest risk group is taken as the
normal group, then values for any other group that fall
o u t s i d et h er a n g eo ft h em e a n±2 s can be considered
abnormal expression values.
Figure 11(A) shows the expression values of Pms2
plotted against the expression values of Ercc1 for each
sample. In Figure 11(A), the mean and -2s values of
Pms2 for the lowest risk group A patients are shown by
Figure 6 Sequential tissue sections with discordant expression
of Pms2, Ercc1 and Xpf. These crypts are from the biopsy of a 71
year old female patient who had a 1 cm adenocarcinoma. While
Pms2 and Xpf have reduced expression in this tissue area, Ercc1 has
high expression. In this mucosal area, one crypt is apparently
fissioning into 3 crypts. Images taken at 200×.
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mean value (black line) was 90.26 percent high expres-
sion for all absorptive cells in the bodies of the crypts in
a tissue section (the value shown in the small box at the
top of the black line). Two standard deviations below
this mean value (shown by the red line) was 77.44 per-
cent high expression (shown in the small box at the top
of the red line). All expression values to the left of the
-2s line can be regarded as representing deficient Pms2
expression. Likewise, the mean and -2s values for Ercc1
expression are shown by two horizontal lines near the
top of the diagram, with the mean value of 97.15 shown
in the black line and the -2s value of 92.89 shown in
the red line. All values below the -2s line can be
regarded as representing deficient Ercc1 expression.
There were 63 samples deficient for Pms2. Of these 63
samples, 56 (89%) of samples were also deficient for
Ercc1. Overall, 85 samples jointly stained for Ercc1 and
Pms2 were deficient for Ercc1. Of these, 56 (66%) were
also deficient in Pms2 expression. Thus a higher percen-
tage of Pms deficient samples were also deficient for
Ercc1 (89%), than Ercc1 samples were deficient in Pms2
(66%). This could parallel the situation found by Nara et
al. [34] where defects in Pms2, an apoptosis (and mis-
match repair) gene, were selected for once Ercc1 was
defective, but other apoptosis genes were alternatively
selected for once Ercc1 was defective, as described
further in the Discussion, below. The overlap between
Pms2 and Ercc1 deficiencies is shown in the Venn dia-
gram of Figure 12.
Figure 11(B) shows the expression values of Ercc1
plotted against the expression values of Xpf when
sequential tissue sections were immunostained for Ercc1
and Xpf respectively. Overall, 81 tissue samples jointly
stained for Ercc1 and Xpf were deficient in Ercc1. Of
these, 43 (53%) were also deficient in Xpf expression.
Also 53 samples were deficient for Xpf. Of these sam-
ples, 43 (81%) were also deficient for Ercc1. Thus a
higher percentage of Xpf deficient samples were also
deficient in Ercc1 (81%), than Ercc1 samples were defi-
cient in Xpf (53%). These overlapping deficiencies are
illustrated in Figure 12.
Figure 11(C) shows the expression values of Pms2
plotted against the expression values of Xpf for each
sample when both were available for the samples. Over-
all, 62 samples are deficient for Pms2. Of these, 41 sam-
ples (66%) were also deficient for Xpf. There were 52
samples deficient for Xpf. Of these, 41 (79%) were also
deficient in Pms2. The overlap between Pms2 and Xpf
is shown in Figure 12.
Extent of the field defects with reduced expression of
Pms2 and Ercc1
We next consider the extent of the field defects that are
deficient in Pms2 and Ercc1 in colon segments that
were resected, due either to the presence of colon can-
cer or due to large tubulovillous adenomas. Crypts were
scored in tissue sections for percent of crypts with high
expression of Pms2, Ercc1 or Ku86. Data derived from 8
patients with a colonic adenocarcinoma and 8 patients
with a large tubulovillous adenoma (TVA) are shown in
Table 1. Where possible, we took 6 tissue samples from
both sides of a colon cancer at distances of 1, 3 and 10
cm to the proximal side and 1, 3 and 10 cm to the distal
side within a colon resection, such as that partially
shown in Figure 13 (a ruler is present for measure-
ments). For resections with large TVAs, we took sam-
ples 1 cm and 10 cm from the tumors. Thus, about 18
cm in length of colonic mucosa for cancer resections
and about 9 cm in length for TVAs were sampled.
Tissue sections were cut from these tissue samples,
immunostained for Pms2, Ercc1 and Ku86, and
Figure 7 Absorptive cells and goblet cells in crypts express DNA repair proteins differently. These three panels show parts of single
crypts from a biopsy of a male patient who had a 1.5 cm tubular adenoma, stained by IHC for Pms2 (A), Ercc1 (B) and Xpf (C). Goblet cells of
the crypts have a large “balloon like” region containing mucin granules (cytoplasmic white areas under these staining conditions). The other cells
in the crypts are absorptive cells. Arrows indicate some nuclei of goblet cells (on the outer edges of the crypts) that have reduced or absent
expression for Pms2, Ercc1 and Xpf. Images taken at 1000×.
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The number of crypts evaluated for each patient is
shown in Table 1. A streaming video, as a microscope is
used to pan through a tissue section while crypts are
evaluated for level of expression, is shown in the public
access video publication by Nguyen et al. [35] at min-
utes:seconds 17:40 to 21:51. In this segment of the
video, 33% of crypts had high Ercc1 expression and 67%
of crypts had reduced expression. The next section of
the video shows a tissue section with only 1% of crypts
(a single crypt) with high expression of both Ercc1 and
Pms2 at minutes:seconds 21:51 to 23:50. A following
segment of this video shows evaluation of Ku86 in a tis-
sue section. (Viewing of different segments of this video
is best done after downloading the entire 345 MB
video.)
The frequency of crypts with high expression for each
p r o t e i ni ss h o w ni nT a b l e1 .F r o m1 6p a t i e n t s ,4o f6 0
samples, or 7%, had high expression of either Pms2 or
Ercc1 (more than 85% of crypts with high expression).
Figure 8 Two pairs of entire tissue sections with consistent protein expression throughout all the crypts. Panels A and C are sequential
tissue sections from a biopsy taken from a 57 year old male patient with current tubulovillous adenomas and a history of colon cancer. Panels B
and D are non-sequential tissue sections from a tissue sample taken from a resection from a male patient who had a carcinoma in the sigmoid.
Panels A and B were stained for Pms2, panels C and D were stained for XPF. All crypts in each tissue section had similar levels of protein
expression, with high (A, C) or low (B, D) protein expression. Images B and D were tiled, since the entire tissue section could not be captured in
one field of view. Images taken at 40×.
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sion of Ku86. A graphical representation of the results
from patient C1 is shown in Figure 14.
A diagram of the human lower gastrointestinal tract is
shown in Figure 15. The colon is considered to be the
areas of ascending, transverse and descending/sigmoid
colon. In the standard diagram shown in Figure 15, the
total length of the lower gastrointestinal tract is repre-
sented as 150 cm, with the colon (from the cecum to
the rectosigmoid junction) being 130 cm. This is consis-
tent with the lengths of colon measured in living indivi-
duals (reviewed in [36]). From our observations of 32
resected colon segments, with 12 in the ascending
colon, 6 in the transverse colon and 14 in the descend-
ing/sigmoid colon (Table 2) and taking an average of
the inner circumferences of the three regions, we deter-
mined that 6.2 cm is the average inner circumference of
the colon (see Figure 13 for how inner circumferences
were measured, after colon segments were opened
longitudinally).
From the images of colonic mucosa in reference [12],
where tissue sections are cut either through the short axes
of crypts or through their long axes, and the images
include reference size bars, we see that there are about
100 crypts per sq mm in the colonic epithelium. The inner
longitudinal dimension of the freshly obtained, non-fixed
human colon (from 100 male and 100 female cadavers,
measured a few hours after being brought to the labora-
tory, or after the intestinal tracts were preserved in a
refrigerator at 3°C for 24-72 hours) is, on average, 160.5
cm (measured from the bottom of the cecum to the color-
ectal junction) with a range of 80 cm to 313 cm [36]. The
intestine lengthens after death, possibly because of loss of
intestinal muscular tone (reviewed in [36]). Thus, a 160.5
cm length is consistent with the length shown in Figure
15, representing the living colon. Using the length of 160.5
cm and an average of 6.2 cm for the inner circumference
of the colon, the inner mucosa would have a surface area,
on average, of about 995 sq cm, or about 9,950,000 (close
to 10 million) crypts. The crypts are connected through
further epithelial cells at their open ends, forming a micro-
scopically indented epithelial sheet (the indents being the
crypts), covering the average 160.5 by 6.2 cm inner surface
area.
W es a m p l e dt i s s u e sf r o m- 1 0t o- 1a n df r o m1t o1 0
cm on the proximal and distal sides, respectively, of
colon cancers of 8 patients and tissues from 1 cm to 10
cm distant from TVAs. In cancer resections, we sampled
about 18 cm of length (about 11%) of the total lengths
of the colons. This would be an area having a little
more than 1 million crypts. Thus, it appears that a field
defect comprising about 1 million crypts, with most
crypts expressing reduced protein levels of Pms2 and
Ercc1, but high levels of Ku86, surrounds the cancers of
these patients, and likely similar field defects surround
TVAs as well.
Discussion
Pms2 deficiency is not generally due to mutation or
protein degradation
It appears unlikely that most cases of reduced expres-
sion of Pms2 protein that we observed are due to
somatic mutation of the Pms2 gene. Somatic mutations
in DNA repair genes are infrequent in sporadic cancers,
and no Pms2 or Xpf mutations were found in Pms2 and
Xpf gene sequences of 11 colon cancers [37]. Similarly,
Figure 9 A tissue section immunostained for Ku86. A tissue section from a biopsy of a 53 year old male patient who never had a colonic
neoplasia. A small patch of three crypts with reduced expression for Ku86 is shown by arrows.
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deficient and lacking Pms2 expression reported by Tru-
ninger et al. [38], Pms2 was deficient in 103 because of
lack of its pairing partner Mlh1. Pairing of Pms2 with
Mlh1 gives Pms2 its stability [23]. The Mlh1 loss, for
sporadic cancers, was due to epigenetic silencing caused
by promoter methylation in 65 out of 66 cases. In 16
cancers Pms2 was deficient when Mlh1 protein expres-
sion was present. Of these 16 cases, no cause was deter-
mined for 10, but 6 were found to have a heterozygous
germline mutation in Pms2, followed by likely loss of
heterozygosity in the tumor. Thus only 6 of 119 tumors
lacking expression for Pms2 (5%) were due to mutation
in Pms2.
As pointed out in the Background section, it has been
suggested that ROS-caused reduced expression of Pms2
and Ercc1 was due to protein degradation. If this were
so, then Pms2 and Ercc1 would be reduced in a coordi-
nated manner. However, when tissue samples were defi-
cient in Ercc1, only 66% of those samples were also
deficient in Pms2. Figure 7, where expression of Pms2
was reduced and Ercc1 was expressed at a high level,
illustrates discordance. Thus it seems unlikely that Pms2
and Ercc1 are reduced primarily due to ROS-caused
protein degradation.
Most instances of Pms2 deficiency in colon cancers are
due to an epigenetic alteration
As indicated in the previous section, mismatch repair
protein Mlh1 interacts with Pms2. They form the het-
erodimer MutLa that is essential for mismatch repair.
In the absence of its Mlh1 partner, Pms2 is unstable
Figure 10 Tissue samples evaluated with respect to expression of Pms2, Ercc1, Xpf or Ku86. Entire tissue sections were evaluated with
respect to all crypt absorptive cells seen in the tissue or within all cells of epithelial origin within a cancer. Pms2, Ercc1 and Xpf were evaluated
in triplicate sequential 4 micron tissues sections of the same tissue samples. Ku86 tissue samples were from similar, but not identical, tissues to
those evaluated for Pms2, Ercc1 and Xpf. Tissue samples from patients at different risks for colon cancer, or from colon segments resected
because of colon cancer, were labeled A, B, C, D, E, F, G and the number of tissue samples, from different patients, evaluated for protein
expression are shown in parentheses under their label. The tissue samples were from colonic biopsies from patients who had (A) never had an
adenoma; (B) 1 to 3 adenomas < 1 cm; (C) advanced neoplasia with either adenoma > 1 cm, villous adenoma, or adenoma with dysplasia; (D)
previous colon cancer; or from colonic resections with (E) tissue sample 1 to 10 cm distant from an adenocarcinoma; (F) area marginal to the
tumor; or (G) epithelial origin cells within the adenocarcinoma.
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was reduced in 119 tumors, for 103 (87%) of the tumors
the human mlh1 gene was transcriptionally silenced by
promoter methylation [38]. The microRNA, miR-155, is
over-expressed in colon tumors as well, and also down-
regulates Mlh1 [39], which in turn would cause reduced
expression of Pms2. As reviewed by Valeri et al. [39],
miRNA transcription levels are frequently controlled by
epigenetic factors including DNA methylation (by DNA
methyltransfereases or DNMTs), histone modification
(by histone methylation or histone deacetylases or
HDACs), or by the polycomb repressive complex 2
(PRC2). Thus, the majority of instances of reduced
Pms2 are likely due to epigenetic alterations.
Ercc1 and Xpf deficiencies are not likely due to mutation
or protein degradation
In the present study, deficient expression of Ercc1 fol-
lows a pattern where the cells near the top of indivi-
dual crypts recover from the deficiency. Xpf has a
similar, though less pronounced pattern of expression.
These observations are inconsistent with a somatic
mutation in the crypt cell lineage, where the stem cells
are at the base of the crypts and their descendents
progressively move towards the top of the crypt [5,6].
In addition, as noted above, no Pms2 or Xpf mutations
were found in Pms2 and Xpf gene sequences of 11
colon cancers [37].
Figure 11 Each dot represents the joint evaluation of a tissue
sample for 2 DNA repair proteins. The colors of the dots a, b, c,
d, e, f, g represent tissues of groups A, B, C, D, E, F, G respectively,
defined in Figure 10. Black lines represent mean values of
expression of tissue sections from group A while red lines represent
values of expression which are -2s less than the mean values.
Numbers in the small boxes show the mean and -2s expression
values. Dots that are below and to the left of the red lines have
significantly reduced expression for both proteins being evaluated.
Figure 12 A Venn diagram illustrating the level of concordance
of deficiencies of Pms2, Ercc1 and XPF. Entire tissue sections
were evaluated with respect to all crypt absorptive cells seen in the
tissue or within all cells of epithelial origin within a cancer. Pms2,
Ercc1 and Xpf were evaluated in triplicate sequential 4 micron
tissues sections of the same tissue samples.
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Ercc1 and Xpf that we observed would be due to post-
translational modifications of the proteins, such as
degradation of the proteins by ROS. While Pms2 and
Ercc1 have both been shown to be subject to degrada-
tion by ROS, 34% of the tissue samples deficient for
Ercc1 were not deficient for Pms2. This lack of consis-
tent simultaneous deficiency in Pms2 and Ercc1 indi-
cates that, in the tissues we evaluated, protein
degradation due to ROS is not likely to be the primary
source of reduced expression.
Ercc1, and possibly Xpf, deficiency is likely due to an
epigenetic alteration
Reduction in Ercc1 protein expression could be caused
by an epigenetic mechanism. A TAR miRNA, coded for
by the HIV virus, down-regulates Ercc1 protein expres-
sion [40]. TAR miRNA allows Ercc1 mRNA to be
Table 1 Percent of crypts which showed high expression of Pms2, Ercc1 or Ku86
Patient designation C =
cancer A = adenoma
Total crypts evaluated (# of
tissue samples)
% Pms2 high in each
tissue section
% Ercc1 high in each
tissue section
% Ku86 high in each
tissue section
C1 958 (6) 22,15,42,1,22,13 40,18,19,29,10,16 98,100,93,96,99,100
C2 921 (5) 32,31,9,1,17,- 26,13,25,10,13,- 99,98,100,99,99,-
C3 968 (6) 33,87,5,1,1,0 91,5,92,21,11,97 N.D.
C4 2,411 (6) 1,4,0,0,1,8 5,11,9,8,11,18 N.D.
C5 448 (4) -,0,0,0,-,0 -,0,4,12,-,15 N.D.
C6 1,801 (5) 7,1,32,-,11,0 38,87,18,-,1,6 N.D.
C7 2,844 (6) 2,58,43,2,2,3 -,52,45,48,70,52 N.D.
C8 1,742 (6) 1,3,1,0,1,2 4,5,10,6,13,8 97,97,97,100,99,99
A1 433 (2) 14,19 7,3 99,-
A2 195 (2) 2,16 16,20 79,75
A3 90 (2) 0,0 2,27 100,-
A4 112 (2) 0,0 24,14 92,87
A5 129 (2) 0,0 10,24 64,98
A6 72 (2) 0,3 15,18 89,89
A7 255 (2) 5,9 37,29 94,48
A8 203 (2) 0,0 15,29 100,95
Percent of crypts with high expression in cancer resections are shown in order, from left to right, for 10, 3 or 1 cm proximal to and for 1, 3 or 10 cm distal tot h e
cancer. Percent of crypts with high expression in tubulovillus adenoma resections are shown in order 10 cm and 1 cm from the tumor. A dash indicates that the
tissue sample was not available for immunostaining. N.D. indicates Not Done
Figure 13 Part of a sigmoid area colon resection, opened
longitudinally, and showing a colon cancer. Tissue samples were
obtained from such freshly resected colon segments. A ruler was
placed across the opened colon segment to determine the inner
circumference of the opened colon segment.
Figure 14 Percent of crypts with high expression of Pms2,
Ercc1 or Xpf. Tissue samples were taken at the indicated distances
from a colon cancer. The distances are -10, -3 or -1 cm on the
proximal side and 1, 3 and 10 cm on the distal side of a resection
from patient C1 (from Table 1). The symbols indicate the percent of
crypts showing high expression of Pms2, Ercc1 or Ku86 in each
tissue sample.
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translation of Ercc1 protein. (A p-body is a cytoplasmic
granule “processing body” that interacts with miRNAs
to repress translation or trigger degradation of target
RNAs.) A survey of miRNA homology regions to human
Ercc1 mRNA [41] indicated at least 21 miRNAs had
regions of homology to Ercc1 mRNA that could act to
decrease Ercc1 mRNA translation (Xpf had no reported
homologous miRNA). As noted above, a review by
Valeri et al. [39] indicated that miRNA transcription
levels are frequently controlled by epigenetic factors.
We observed that cancers frequently had areas with
restored expression of Pms2, Ercc1 and/or Xpf, even
though surrounding areas of the cancers had reduced
levels of Pms2, Ercc1 and/or Xpf. This could indicate
selection of sub-clones for which epigenetically reduced
expression of Pms2, Ercc1 and/or Xpf was reversed
under the new micro-environment of a growing cancer.
Elimination of factors at the transcriptional level, or
protein turnover level, that might reduce protein
expression of Ercc1
McGurk et al. [42] examined and eliminated a number
of factors that might control protein expression levels of
Ercc1. They first established that Ercc1 mRNA could
occur as either the wild-type sequence or in three splice
variants (one generating a larger protein than wild-type).
Each of the splice variants could produce proteins lack-
ing the Xpf binding region. Ercc1 mRNA was also
found to have either wild-type or three alternative tran-
scription start points. Neither the level of overall mRNA
transcription, splice variation nor transcription start
point of mRNA correlated with protein level of Ercc1.
Rate of Ercc1 protein turnover also did not correlate
with Ercc1 protein level. Ercc1 transcripts with longer
or shorter 5’-UTRs were, as well, not responsible for
levels of Ercc1 protein. They concluded that control of
Ercc1 protein level occurred at the translational level.
Coordination, and non-coordination, of protein levels of
Ercc1 and Xpf
Explanations are needed both for when Ercc1 and Xpf
have coordinated lack of expression in nuclei, and also
for when their protein expression is discordant (Figure 7
and Figure 12).
Early reports indicated that Ercc1 was not stable in
the absence of Xpf [43,44], and similarly, Xpf was
reported to be unstable in the absence of Ercc1 [44].
More recent results modified these observations, since
knockdown of Xpf mRNA expression by siRNA (and
consequent loss of Xpf protein expression) did not elim-
inate protein expression of Ercc1 in a human cancer cell
line [45]. However, the location of the Ercc1 expression
in the cells, under conditions of the siRNA knockdown
of Xpf was not determined, so it is not clear whether
the continued expression of Ercc1 resulted in nuclear
location of the Ercc1. In our open access video publica-
tion [35] at minutes:seconds 11:35 to 12:43, we illustrate
that when Ercc1 is low in the nucleus it may build up in
the cytoplasm. Ercc1 was first thought to have its own
nuclear localization signal (NLS) (note added in proof to
[46]). Since Ercc1 had one NLS but did not have a clus-
ter of NLSs, it was later suggested that Ercc1 may
depend upon its binding with Xpf for its nuclear import,
since Xpf appeared to have 4 NLSs [47]. A recent report
b yA h m a de ta l .[ 4 8 ]f o u n dt h a tm u t a n tX p fp r o t e i n
could bind to Ercc1 and prevent Ercc1 (and Xpf) from
entering the nucleus. From these reports, the simulta-
neous reduced or absent protein expression of Ercc1
Figure 15 Diagram of the human lower gastrointestinal tract.
This diagram illustrates the locations of the regions referred to in
Table 2. Distances from the anal verge are shown in centimeters.
Table 2 Inner circumference* of regions of the lower gastrointestinal tract
Region of lower GI tract Number of resections measured Mean inner circumference +/- S.E.M. Range of values
Cecum 12 8.7 +/- 0.3 cm 8-10.5 cm
Ascending colon 12 6.6 +/- 0.1 cm 6-7 cm
Transverse colon 6 5.8 +/- 0.3 cm 5-6.5 cm
Descending/Sigmoid colon 14 6.3 +/- 0.1 cm 6-6.8 cm
Rectum near rectal/sigmoid junction 12 5.7+/- 0.4 cm 4.5-7.5 cm
*Measured within 20-30 minutes of removal from the body
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tent with these reports, we found that for 81 tissue sam-
ples deficient in Ercc1, 43 (53%) were also deficient in
Xpf expression. In the reverse evaluation, when 53 sam-
ples were deficient for Xpf, 43 (81%) of these samples
were also deficient for Ercc1.
However, our results showed that 31 out of 81 (47%)
of tissue samples deficient in Ercc1 still had high
nuclear expression of Xpf, and 10 out of 53 (19%) tissue
samples deficient in nuclear Xpf still had high nuclear
expression of Ercc1.
One possible reason for why protein expression of
Ercc1 and Xpf can be discordant may be that the cells
in which Ercc1 and Xpf were shown to be unstable in
the absence of each other were not of colonic epithelial
origin [43,44]. It may be that Ercc1 and Xpf have other
pairing partners that are sometimes high in cells of
colonic epithelial origin, and in such cells could give
Ercc1 or Xpf increased stability, as well as provide a
NLS for bringing Ercc1 or Xpf into the nucleus.
As pointed out by Dingwall and Laskey [49], a protein
without a NLS can still be transported into the nucleus
as part of a complex with a protein that has a nuclear
targeting sequence. Thus, Xpf interacts strongly with
Pcna [50,51] and Pcna has a nuclear locator signal
(NLS) [52]. The Fancg protein has strong affinity for
Ercc1 and moderate affinity for Xpf [53]. Fancg, when
also complexed with Fanca, is transported to the
nucleus [54]. Ercc1 and Xpf each bind to Msh2 [55].
Msh2 has two NLSs [56]. Ercc1 has a binding domain
for Xpa [57,58], and Xpa has a NLS [59]. Therefore, it is
possible that, in some tissues progressing to cancer, one
or more of these proteins that interact with Ercc1 and/
or Xpf may provide both stability and nuclear transport
for one member of the pair when the other is reduced
or absent.
Coordination, and non-coordination, of protein levels of
Pms2 with Ercc1 and Xpf
Deficiencies in expression of Pms2 are either coordi-
nated or un-coordinated with deficiencies in Ercc1 and/
or Xpf. This is indicated in Figures 4, 5, 6, 7, 11 and 12.
For 63 samples deficient for Pms2, 56 (89%) were also
deficient for Ercc1 and for 85 samples deficient for
Ercc1, 56 (66%) were also deficient in Pms2 expression.
Deficiency in Ercc1 and Xpf likely correlates with defi-
ciency in Pms2 because a defect in Pms2 (causing apop-
tosis resistance) would be selected for in the face of the
increased DNA damages accumulated when Ercc1 and/
or Xpf are deficient. This is supported by the results of
Nara et al. [34], who showed that when Ercc1 deficient
Chinese hamster ovary cells were repeatedly subjected
to DNA damage, of five clones derived from the surviv-
ing cells, three were mutated in Pms2.
The fact that a deficiency of Ercc1 and/or Xpf is
sometimes present without a Pms2 deficiency may also
be explained by the results of Nara et al. [34]. The other
two clones derived from surviving cells, in the experi-
ment above, were mutated in Msh2 and Msh6, two
other mismatch repair proteins that also have essential
roles in apoptosis (reviewed in [20]). Deficiencies in one
of these proteins could be selected for, rather than
Pms2, to protect cells deficient in Ercc1 or Xpf (and
thus accumulating DNA damages) from apoptosis.
Likely role of deficiencies in Pms2, Ercc1 and Xpf in
progression to colon cancer
In the study of Nara et al. [34], ercc1, pms2 double
mutant Chinese hamster ovary cells, when exposed to
UV light (a DNA damaging agent), showed a 7,375-fold
greater mutation frequency than wild-type Chinese ham-
ster ovary cells, and a 967-fold greater mutation fre-
quency than the cells defective in Ercc1, alone. Thus
colonic cells deficient in both Ercc1 and Pms2 would be
genetically unstable. A similar genetically unstable situa-
tion would be expected for cells doubly defective for
Pms2 and Xpf. This instability would be expected to
enhance progression to colon cancer by causing a muta-
tor phenotype [60], and could also account for the pre-
sence of the cells doubly deficient in Pms2 and Ercc1
(or Xpf) we observed in field defects associated with
colon cancer.
Alterations in other apoptosis proteins appear to be later
events in progression to colon cancer
Both deficiency of CcOI and increased Maspin protein
expression appear to cause apoptosis resistance, as
reviewed for CcOI by Bernstein et al. [12], and shown
for Maspin by Payne et al. [61]. Immunohistochemical
evaluations were made for deficiency of cytochrome
coxidase subunit I (CcOI) [12] or increased expression
of Maspin [61] in colonic epithelium. These evaluations
were made in tissues from biopsies of patients with no
history of colonic neoplasia, from tissue samples taken
from resections 1-10 cm distant from colon cancers, tis-
sues at the margins of cancers and tissue samples within
cancers (and for Maspin, also within adenomas). As
noted above, resistance to apoptosis may allow cells
with DNA damage to survive, leading to increased chro-
mosomal instability and, potentially, progression to
colon cancer.
CcOI is coded for by mitochondrial DNA and CcOI
protein deficiency of a crypt is known to arise from
mutation of the CcOI gene [10]. While there was
increased frequency of crypts with CcOI deficiency in
tissues 1-10 cm from colon cancers, there were no large
patches of crypts with CcOI deficiency in these tissues.
Only in tissues at the margins of crypts were large
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CcOI-deficient crypts, observed [12]. That is, in Figure
1, large CcOI-deficient patches would occur in the irre-
gular circle just outside of the irregular circle denoting a
cancer. This indicates that colon cancers may arise from
CcOI deficient patches of crypts, but this CcOI defi-
ciency may occur and grow into a large patch at a later
s t a g ei np r o g r e s s i o nt oc o l o nc a n c e rt h a nd e f i c i e n c yf o r
Pms2, Ercc1 or Xpf, which may occur in as many as 1
million crypts surrounding colon cancers.
Strongly increased maspin protein expression was only
seen in polyps or in colon cancers, but not in tissues
surrounding cancers [61]. Thus, increased maspin
expression is likely among the last changes in formation
of a colon cancer.
Conclusions and implications
Overall, substantial deficiencies in protein expression of
DNA repair proteins Pms2, Ercc1 and Xpf frequently
occur in a coordinated manner in extensive regions,
involving as many as 1 million crypts, near cancers, and
also occur within cancers. This suggests that colon can-
cers tend to arise in field defects that are deficient in
DNA repair and that deficiencies in protein expression
of Pms2, Ercc1 and Xpf are frequent early, and often
coordinated, steps in progression to colon cancer, as
well as further progression within cancers.
Our results suggest that blocking any one oncogenic
pathway in a colon cancer may only slow down further
progression, if the cancer was already deficient in DNA
repair. Reduced DNA repair capability combined with
increased apoptosis resistance in a cancer, and any
metastasized cells from the cancer, would tend to
i n c r e a s eD N Ad a m a g e st h a tg i v er i s et of u r t h e rm u t a -
tions after DNA replication, likely unleashing other
pathways of progression.
Our findings also suggest that the current therapeutic
approach to treating colon cancer, with surgical removal
of the cancer and a good part of the surrounding field
defect, is fairly effective, since it would remove many of
the secondary and tertiary mutations leading to the can-
cer. However, this could be followed by use of therapeu-
tic DNA damaging agents. Remaining parts of the field
defect (and any metastasized cells) would be more defi-
cient in DNA repair than the surrounding normal areas
of the colon, outside the field defect.
In addition, it was recently found that inhibition of an
additional DNA repair enzyme - such as inhibition of
the repair enzyme PARP in breast cancer - facilitates
killing of tumor cells [62]. Similar further DNA repair
inhibition in the case of colon cancer could also be pur-
sued. This may cause repair deficient cells in a remain-
ing portion of a field defect, or in metastasized cells, to
be even more susceptible to the killing effects of thera-
peutic DNA damaging agents.
Methods
Tissue procurement
Before any biopsy tissue samples were obtained during
colonoscopy, informed consent was given by the patient,
u s i n gaf o r ma p p r o v e db yt h eU n i v e r s i t yo fA r i z o n a
Institutional Review Board. Biopsied colonic mucosal
samples were fixed in 10% buffered formalin for 4
hours, then transferred to 70% alcohol, followed by par-
affin embedment. Tissue samples from colonic resec-
tions were obtained after informed consent before
surgery, and these larger tissue samples were fixed in
10% buffered formalin for 24 to 36 hours, then trans-
ferred to 70% alcohol, followed by paraffin embedment.
Overall, tissue biopsies were taken during colonosco-
pies of 77 patients at 4 different risk levels for colon
cancer, including 19 patients who had never had colonic
neoplasia (who served as controls). In addition, 158 tis-
sue samples were taken from tissues near or within
colon cancers removed by resection and 16 tissue sam-
ples were taken near tubulovillous adenomas (TVAs)
removed by resection. A total of 568 triplicate tissue
sections (a total of 1,704 tissue sections, obtained as
d e s c r i b e db e l o w )f r o mt h e s et i s s u es a m p l e sw e r ee v a l u -
ated by immunohistochemistry for one of 4 DNA repair
proteins.
Immunohistochemical procedure
The general procedures used were demonstrated in the
first 8 minutes of our methods video publication [35].
Briefly, 4 μm sections were cut from formalin-fixed and
paraffin-embedded tissues and placed on slides. Tissue
sections for staining with Pms2, Ercc1 and Xpf were
placed on slides so that cuts 1, 4 and 7 were placed on
the slide for Pms2, cuts 2, 5 and 8 were placed on the
slide for Ercc1, and cuts 3, 6 and 9 were placed on the
slide for Xpf. For staining with Ku86, three sequential
cuts were placed on one slide. These multiple tissue sec-
tions were used in order to be sure that areas with
absent staining were not due to bubbles that may have
prevented the antibodies from reaching a given tissue
area, and to allow comparisons of at least two tissue
sections even when one of the three tissue sections on a
slide may have had a fold in an area. Sections were
deparaffinized with Xylene and graded ethanols, then
rehydrated.
Antigen retrieval was performed by microwave expo-
sure in VECTOR Antigen Unmasking Solution
(obtained from Vector Laboratories, inc., Burlingame,
CA) according to the manufacturer’s instructions. The
slides were then rinsed with distilled water.
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bation in 3% hydrogen peroxide in methanol for 20 min,
and then the tissue sections were rinsed with distilled
water, “TBST” buffer [1 ml Tween + 100 ml 10x Tris +
900 ml distilled water (where 10x Tris is 24.2 grams
Trizma + 80 grams NaCl + 1,000 ml distilled and deio-
nized water + concentrated HCl {approximately 15 ml}
to bring the solution to pH 7.6)], and PBS. The TBST
step is not used with the Ercc1 or Ku-86 protocol.
Slides were placed in Sequenza staining racks (Shan-
don Sequenza Immunostaining System from Thermo
Scientific, Thermo Fisher Scientific Inc., Waltham, MA)
and rinsed with PBS. For ERCC1, PMS2 and XPF, 3
drops/slide of “Background Sniper” (from Biocare Mach
3 kit, Biocare Medical, Concord CA) were added and
left for 10 min at room temperature (RT) to reduce
non-specific staining of background proteins. For Ku86,
150 ul of 1.5% normal goat serum in 2% BSA/PBS was
used for one hour. The slides were rinsed with TBST
(PBS was used instead of TBST for Ercc1).
A primary mouse monoclonal antibody was used for
Pms2 (Pharmingen, Becton, Dickinson and Company,
San Diego CA); Ercc1 (8F1 from Neomarkers, Freemont
CA); or Xpf (3F2/3 obtained from Abcam plc. San Fran-
cisco, CA). Ku-86 (H-300 obtained from Santa Cruz
Biotechnology, inc., Santa Cruz, CA) is a rabbit polyclo-
nal antibody.
125 ul primary antibody was added as follows: Pms2
mouse monoclonal antibody was added at 10 μg/ml in
2% BSA/TBST mixture and left to incubate at RT for 2
hours before 3 TBST rinses were applied. Ercc1 mouse
monoclonal antibody was added at 2 μg/ml in 2% BSA/
PBS and left to incubate at room temperature for 45
minutes before 3 PBS washes. Xpf mouse monoclonal
antibody was added at 5 μg/ml in Renoir Red (from Bio-
care Mach 3 kit, Biocare Medical, Concord CA), and
incubated for 1 hour at room temperature, followed by
3 TBST rinses. Ku-86 primary rabbit polyclonal anti-
body was added at 2 ug/ml diluted in 2% normal goat
serum in 2% BSA/PBS and incubated for 1 hour at
room temperature, followed by 3 TBST rinses.
Secondary antibody was added as follows: For Pms2,
the polyclonal rabbit anti-mouse Dako Biotinylated sec-
ondary antibody (E0413, DAKO Corp., Carpinteria, CA)
was added at 120 μl/slide at a 1:100 dilution (in 2%
BSA/TBST) to the slides and incubated for 30 minutes
at room temperature before being rinsed 3 times with
TBST.
For Ercc1, the same Dako secondary antibody as
above was added to the slides at 120 μl/slide at a 1:300
dilution (in 2% BSA/PBS) and incubated for 30 minutes
before 3 PBS washes. The Dako secondary antibody was
n o tu s e df o rX p f .F o rX p f ,M o u s eP r o b ea n dM o u s e
Polymer (Biocare Mach 3 kit, Biocare Medical, Concord
CA) were used instead of Dako secondary antibody.
Mouse Polymer HRP was added at 4 drops/slide for 15
min, followed by TBST and PBS rinses. For Ku-86, Goat
anti-rabbit biotinylated IgG secondary antibody was
used (BA-1000 Vector Laboratories, inc., Burlingame
CA) at a 1:100 ratio diluted into 2% BSA/PBS at 120 ul/
slide for 30 minutes, followed by 3 PBS rinses.
Vectastain Elite avidin-biotin complex method kit PK
6100 (Vector Laboratories, inc., Burlingame, CA) was
then used according to the manufacturer’s instructions
in the Pms2, Ercc1, and Ku-86 protocols at 3 drops/
slide and incubated at room temperature for 30 minutes
before 2 rinses with TBST(for Pms2) and PBS (for Ercc1
and Ku86). For XPF, four drops/slide of Mouse Probe
were added for 15 min, followed by 3 TBST rinses.
The slides were then removed from the Sequenzas,
and color development was carried out by applying
.025% diaminobenzidine tetrachloride (Sigma, St. Louis,
MO) in PBS supplemented with 0.04% hydrogen perox-
ide. Sections were counterstained with 1:4 diluted hema-
toxylin (Sigma), dehydrated in a graded series of
ethanols followed by xylene, and then mounted with
coverslips using Cytoseal XYL (Richard Allen Scientific,
Kalamazoo, MI). Brown staining indicates Pms2, Ercc1,
Xpf, or Ku-86 expression, and blue staining from hema-
toxylin identifies nucleoproteins in the nucleus. Table 3
briefly outlines the steps used for IHC of the four pro-
teins in a tabular form, to make the four different proto-
cols more easily followed.
Quantitation of high or reduced expression of Pms2,
Ercc1, Xpf, and Ku86
After being prepared using the immunohistochemical
procedure, slides were viewed with a Motic BA300 digi-
tal photomicroscope, and the level of immunohisto-
chemical staining was evaluated both directly with the
microscope and with a digital image on a computer
monitor, using Motic Images Plus version 2.0 software.
The software was set with Gain 0, Offset 0, Enhance dis-
abled, Gamma disabled, R,G,B of gain 1, brightness 0,
Edge Detection disabled, Sharpness disabled, Resolution
1024/768, White Balance on, Auto Exposure on and
then switched off with an increase in brightness suffi-
cient to allow background (in areas of the slide without
tissue present) to become white or nearly white.
The colonic crypts were divided into colonic lumen
surface, crypt neck, and crypt body, as shown in the
Results (Figure 3). Colonic crypts are composed primar-
ily of absorptive cells and goblet cells. Goblet cell nuclei
had variable levels of expression of the proteins of inter-
est, while absorptive cell nuclei of the bodies of crypts
were consistent in expression of the proteins of interest
from the stem cell region at the base of the crypts to
the neck region of crypts. For the semi-quantitative
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or Xpf, frequencies of high expression of the proteins of
interest in absorptive cell nuclei of the bodies of crypts
were assessed for the entire piece of tissue seen in the
tissue section. Thus, a value of 20% assigned to a tissue
section would indicate that 20% of the absorptive cell
nuclei in the bodies of crypts had high expression for
the protein being evaluated (there were usually 30-150
identifiable body sections of crypts seen per tissue sec-
tion). For values of Ku86 shown in Figures 10, 11 and
12, the values are expressed as percent of entire crypts
showing high expression of the protein, since Ku86 pro-
tein expression was either high or very low in individual
crypts.
Table 3 Tabular form of IHC
Pms2 Ercc1 Xpf Ku86
Cut 4 micron sections Cut 4 micron sections Cut 4 micron sections Cut 4 micron sections
Deparaffinize and rehydrate Deparaffinize and rehydrate Deparaffinize and rehydrate Deparaffinize and rehydrate
Antigen retrieval in microwave with
VECTOR Antigen Unmasking Solution
Antigen retrieval in microwave with
VECTOR Antigen Unmasking Solution
Antigen retrieval in
microwave with VECTOR
Antigen Unmasking
Solution
Antigen retrieval in microwave
with VECTOR Antigen
Unmasking Solution
Rinse with PBS and distilled water Rinse with PBS and distilled H2O Rinse with PBS and distilled
water
Rinse with PBS and distilled
water
Incubate in 3% H2O2 in methanol for 20
min
Incubate in 3% H2O2 in methanol for 20
min
Incubate in 3% H2O2 in
methanol for 20 min
Incubate in 3% H2O2 in
methanol for 20 min
Rinse in distilled water, PBS Rinse in distilled water, PBS Rinse in distilled water,
TBST, PBS
Rinse in distilled water, PBS
Place in Sequenza racks, rinse with PBS Place in Sequenza racks, rinse with PBS Place in Sequenza racks,
rinse with PBS
Place in Sequenza racks, rinse
with PBS
Add 3 drops Background Sniper, 10 min
at room temp
Add 3 drops Background Sniper, 10 min
at room temp
Add 3 drops Background
Sniper, 10 min at room
temp
Add 1.5% normal goat serum in
2%
BSA/PBS, 120 μl, one hour
Rinse with TBST Rinse with PBS Rinse with TBST Do Not Rinse
Primary mouse monoclonal from
Pharmingen at 10 μg/ml into 2% BSA/
TBST, 120 μl/slide
Primary mouse monoclonal 8F1 from
Neomarkers at 2 μg/ml with 2% BSA/
PBS, 120 μl/slide
Primary rabbit polyclonal
3F2/3 from Abcam at 5 μg/
ml in Renoir Red at 120 μl/
slide
Primary mouse monoclonal H-
300 from Santa Cruz at 2 μg/ml
in 2% BSA/PBS, 120 μl/slide
Incubate 2 hrs at room temp Incubate 45 min at room temp Incubate 1 hour at room
temp
Incubate 45 min at room temp
3 rinses with TBST 3 rinses with PBS 3 rinses with TBST 3 rinses with PBS
Polyclonal rabbit anit-mouse antibody
Dako Biotinylated secondary antibody at
100 μl/slide at 1:100 dilution in 2% BSA in
TBST
Polyclonal rabbit anit-mouse antibody
Dako Biotinylated secondary antibody at
100 μl/slide at 1:300 dilution in 2% BSA/
PBS
Mouse Probe (Biocare) 4
drops/slide
Goat anti-rabbit biotinylated IgG
secondary antibody at 1:100
dilution in 2% BSA/PBS, 100 μl/
slide
Incubate 30 min at room temp Incubate 30 min at room temp Incubate 15 min room
temp
Incubate 30 min at room temp
3 rinses with TBST 3 rinses with PBS 3 rinses with TBST 3 rinses with PBS
Vectastain Elite avidin-biotin complex
method kit 3 drops/slide
Vectastain Elite avidin-biotin complex
method kit 3 drops/slide
Mouse Polymer (Biocare)
4 drops/slide
Vectastain Elite avidin-biotin
complex method kit 3 drops/
slide
Incubate 30 min room temp Incubate 30 min room temp Incubate 15 min room
temp
Incubate 30 min room temp
2 rinses TBST, then PBS 2 rinses PBS 3 rinses TBST, then PBS 2 rinses PBS
Diaminobenzidine tetrachloride plus
0.04% H2O2
Diaminobenzidine tetrachloride plus
0.04% H2O2
Diaminobenzidine
tetrachloride plus 0.04%
H2O2
Diaminobenzidine tetrachloride
plus 0.04% H2O2
Counterstain with hematoxylin Counterstain with hematoxylin Counterstain with
hematoxylin
Counterstain with hematoxylin
Dehydrate with ethanols followed by
xylene
Dehydrate with ethanols followed by
xylene
Dehydrate with ethanols
followed by xylene
Dehydrate with ethanols
followed by xylene
Mount with Cytoseal and coverslips Mount w/Cytoseal and coverslips Mount with Cytoseal and
coverslips
Mount with Cytoseal and
coverslips
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and Figure 14, a different method was used, where the
percent of crypts having high expression of the protein
was evaluated. Crypts were labeled 0, 1, 2, 3 or 4 for
absent expression, just detectable expression, low
expression, medium high expression or highest expres-
sion, respectively. Those crypts labeled 3 or 4 were con-
sidered to have high expression, and those labeled 0, 1
or 2 were considered to have deficient expression. This
method, for a tissue section with 33% of crypts having
high expression for Ercc1, is illustrated in the public
access video publication by Nguyen et al. [35] at min-
utes:seconds 17:40 to 21:51. The next section of this
video shows a tissue section with very low expression of
both Ercc1 and Pms2 in about 100 crypts but with one
crypt with high expression of both proteins, at minutes:
seconds 21:51 to 23:50 of the 28 minute video. The 345
MB Mpeg4 video can be best downloaded from the
PubMed Central web site, in order to access specific
minutes, and have the ability to replay those sections,
without viewing the entire video.
Statistical analysis
Boxplots, scatter plots and means and standard errors of
the means (Figures 10 and 11 and Table 2, respectively)
were made using SPSS 17.0 software.
Photomicrographs
All micrographs were obtained with a Motic BA300
digital photomicroscope with integrated camera, using
Motic Images Plus version 2.0 software adjusted as
described above. The images were then saved as tif
images, and adjusted in Paint Shop Pro 5 to maximize
brightness and contrast between brown staining repre-
senting expression of the protein being evaluated and
the blue color representing hemotoxylin staining of
DNA.
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